Table 1.
Characteristics of patients who underwent allogeneic transplantation for mycosis fungoides and Sezary syndrome, registered to the CIBMTR, between 2000 and 2009.
| Patient characteristicsa |
NST/RIC N% |
Myeloablative N% |
|---|---|---|
| Patient-related | ||
| Number of patients | 83 | 46 |
| Number of centers | 37 | 31 |
| Age at transplant, median (range) years | 51 (27–72) | 44 (22–63) |
| 21–30 | 1 (1) | 3 (7) |
| 31–40 | 12 (14) | 11 (24) |
| 41–50 | 24 (29) | 21 (46) |
| 51–60 | 35 (42) | 8 (17) |
| > 60 | 11 (13) | 3 (7) |
| Male sex | 52 (63) | 18 (39) |
| Karnofsky score | ||
| < 90 | 32 (39) | 28 (61) |
| ≥ 90 | 35 (42) | 11 (24) |
| Missing | 16 (19) | 7 (15) |
| Self Reported Racial group | ||
| White | 73 (88) | 30 (65) |
| Black | 7 (8) | 15 (33) |
| Asian | 3 (4) | 1 (2) |
| Disease-related | ||
| Disease status at transplant | ||
| Never in CR (PIF) | 31 (37) | 13 (28) |
| First complete remission | 1 (1) | 2 (4) |
| ≥ Second complete remission | 2 (2) | 3 (7) |
| First relapse | 10 (12) | 0 |
| ≥ Second relapse | 12 (14) | 6 (13) |
| Missing | 27 (33) | 22 (48) |
| Interval from diagnosis to transplant, median (range), months | 36 (4–206) | 20 (4–174) |
| <12 | 9 (11) | 12 (26) |
| 12–36 | 33 (40) | 17 (37) |
| > 36 | 41 (49) | 17 (37) |
| Transplant-related | ||
| Graft type | ||
| Bone marrow | 11 (13) | 7 (15) |
| Peripheral blood | 71 (86) | 36 (78) |
| Cord blood | 1 (1) | 3 (7) |
| Year of transplant | ||
| 2000–2002 | 5 (6) | 8 (17) |
| 2003–2005 | 25 (30) | 13 (28) |
| 2006–2008 | 40 (48) | 14 (30) |
| 2009 | 13 (16) | 11 (24) |
| Donor type | ||
| HLA-matched related | 45 (54) | 19 (41) |
| Unrelated donor | 34 (41) | 22 (48) |
| HLA-mismatched related | 4 (5) | 5 (11) |
| Conditioning regimen at transplant | ||
| Fludarabine + Melphalan | 36 (43) | 14 (30) |
| Busulfan + Cyclophosphamide | 0 | 4 (9) |
| Cyclophosphamide + TBI | 3 (4) | 16 (35) |
| Fludarabine + Busulfan ± Other | 30 (36) | 7 (15) |
| TBI only | 9 (11) | 5 (11) |
| BEAM | 2 (2) | 0 |
| TLI + ATG | 3 (4) | 0 |
| GVHD prophylaxis | ||
| In vivo T-cell depletion | 1 (1) | 0 |
| CSA + Alemtuzumab | 0 | 1 (2) |
| CSA ±MTX ± Other | 21 (25) | 8 (17) |
| FK506/CSA + MMF ± Other | 22 (27) | 8 (17) |
| FK506 ± MTX ± Other | 35 (42) | 25 (55) |
| Alemtuzumab alone | 3 (4) | 0 |
| Missing | 1 (1) | 4 (9) |
| Median follow-up of survivors, median (range), months | 39 (3–91) | 32 (3–97) |
Abbreviations: EVAL = evaluable; CMV= cytomegalovirus; NST = non-myeloablative; RIC = reduced intensity conditioning; Cy = cyclosphosphamide; TBI = total body irradiation; GVHD = graft versus host disease; CSA = cyclosporine; MMF= mycophenolate; MTX = methotrexate; FK506 = tacrolimus; HLA= human leukocyte antigen.